Stock Groups

Moderna to develop mRNA-based shingles vaccine -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILEPHOTO: In this illustration, a vial and sryinge can be seen in front a Moderna logo. This was taken on January 11, 2021. REUTERS/Dado Ruvic

(Reuters) – Moderna (NASDAQ:) Inc announced Friday that it was developing three vaccines based upon the same technology as its COVID-19 shot. One of these is for viral infection shingles.

Moderna-rivaled messenger RNA technology (mRNA) was key in the success of COVID-19 vaccinations. Pfizer (NYSE:) This has led to efforts to utilize the innovative technology in other therapies and vaccines for difficult-to-treat conditions.

Pfizer also has a mRNA-based vaccine against shingles in development and plans to start clinical trials by the end of 2022.

If both are successful, they will be competing against GlaxoSmithKline, (NYSE:),’s Shingrix vaccine in two doses, which was approved last year by the U.S. Food and Drug Administration.

Shingles usually develop in people over 60 who are infected by varicella virus or chicken pox. The symptoms include a red, itchy, painful skin that usually disappears within one month.

Moderna’s varicella-zoster vaccine has been developed.

A cancer vaccine is being developed by the company, as well as a shot against herpes virus-2 which causes genital and sexually transmitted disorders.

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. Trading the financial markets is the most risky investment form. Please make sure you are fully aware of all the costs and risks involved.

[ad_2]